The selective accumulation of F16–IL2 around tumour vascular structures in both subcutaneous and intracranial xenografts (Figure 4), the focal recruitment of immune effector cells (Figure 3), and the therapeutic effect on glioblastoma tumours of the F16–IL2 plus temozolomide combination therapy (Figure 2) support the anticancer role of effector cells stimulated by the immunocytokine. Here, IL2 is linked to glioblastoma.